Literature DB >> 24975859

Evaluation and construction of diagnostic criteria for inclusion body myositis.

Thomas E Lloyd1, Andrew L Mammen2, Anthony A Amato2, Michael D Weiss2, Merrilee Needham2, Steven A Greenberg1.   

Abstract

OBJECTIVE: To use patient data to evaluate and construct diagnostic criteria for inclusion body myositis (IBM), a progressive disease of skeletal muscle.
METHODS: The literature was reviewed to identify all previously proposed IBM diagnostic criteria. These criteria were applied through medical records review to 200 patients diagnosed as having IBM and 171 patients diagnosed as having a muscle disease other than IBM by neuromuscular specialists at 2 institutions, and to a validating set of 66 additional patients with IBM from 2 other institutions. Machine learning techniques were used for unbiased construction of diagnostic criteria.
RESULTS: Twenty-four previously proposed IBM diagnostic categories were identified. Twelve categories all performed with high (≥97%) specificity but varied substantially in their sensitivities (11%-84%). The best performing category was European Neuromuscular Centre 2013 probable (sensitivity of 84%). Specialized pathologic features and newly introduced strength criteria (comparative knee extension/hip flexion strength) performed poorly. Unbiased data-directed analysis of 20 features in 371 patients resulted in construction of higher-performing data-derived diagnostic criteria (90% sensitivity and 96% specificity).
CONCLUSIONS: Published expert consensus-derived IBM diagnostic categories have uniformly high specificity but wide-ranging sensitivities. High-performing IBM diagnostic category criteria can be developed directly from principled unbiased analysis of patient data. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that published expert consensus-derived IBM diagnostic categories accurately distinguish IBM from other muscle disease with high specificity but wide-ranging sensitivities.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Year:  2014        PMID: 24975859      PMCID: PMC4132572          DOI: 10.1212/WNL.0000000000000642

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

1.  Epidemiology of inclusion body myositis in the Netherlands: a nationwide study.

Authors:  U A Badrising; M Maat-Schieman; S G van Duinen; F Breedveld; P van Doorn; B van Engelen; F van den Hoogen; J Hoogendijk; C Höweler; A de Jager; F Jennekens; P Koehler; H van der Leeuw; M de Visser; J J Verschuuren; A R Wintzen
Journal:  Neurology       Date:  2000-11-14       Impact factor: 9.910

Review 2.  Inclusion body myositis.

Authors:  Rabi Tawil; Robert C Griggs
Journal:  Curr Opin Rheumatol       Date:  2002-11       Impact factor: 5.006

3.  International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009.

Authors:  Olivier Benveniste; David Hilton-Jones
Journal:  Neuromuscul Disord       Date:  2010-04-21       Impact factor: 4.296

Review 4.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

5.  Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008.

Authors:  D Hilton-Jones; A Miller; M Parton; J Holton; C Sewry; M G Hanna
Journal:  Neuromuscul Disord       Date:  2010-01-13       Impact factor: 4.296

Review 6.  Inclusion body myositis and myopathies.

Authors:  R C Griggs; V Askanas; S DiMauro; A Engel; G Karpati; J R Mendell; L P Rowland
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

7.  Inclusion body myositis presenting as treatment-resistant polymyositis.

Authors:  L H Calabrese; H Mitsumoto; S M Chou
Journal:  Arthritis Rheum       Date:  1987-04

8.  Inclusion body myositis. Observations in 40 patients.

Authors:  B P Lotz; A G Engel; H Nishino; J C Stevens; W J Litchy
Journal:  Brain       Date:  1989-06       Impact factor: 13.501

Review 9.  Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria.

Authors:  Frank L Mastaglia; Beverley A Phillips
Journal:  Rheum Dis Clin North Am       Date:  2002-11       Impact factor: 2.670

10.  Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases.

Authors:  M Needham; I James; A Corbett; T Day; F Christiansen; B Phillips; F L Mastaglia
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-02-07       Impact factor: 10.154

View more
  49 in total

Review 1.  Update on Inclusion Body Myositis.

Authors:  Duaa Jabari; V V Vedanarayanan; Richard J Barohn; Mazen M Dimachkie
Journal:  Curr Rheumatol Rep       Date:  2018-06-28       Impact factor: 4.592

Review 2.  Classification of myositis.

Authors:  Ingrid E Lundberg; Marianne de Visser; Victoria P Werth
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

3.  A Patient with Sjogren's Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis.

Authors:  Jason Hom; Shruti Marwaha; Anna Postolova; Jessie Kittle; Rosaline Vasquez; Jean Davidson; Jennefer Kohler; Annika Dries; Liliana Fernandez-Betancourt; Marta Majcherska; Joanna Dearlove; Shyam Raghavan; Hannes Vogel; Jonathan A Bernstein; Paul Fisher; Euan Ashley; Jacinda Sampson; Matthew Wheeler
Journal:  J Gen Intern Med       Date:  2019-03-18       Impact factor: 5.128

Review 4.  Diagnostic Imaging of Inflammatory Myopathies: New Concepts and a Radiological Approach.

Authors:  Júlio Brandão Guimarães; Marcelo A Nico; Alípio G Omond; Laís Uyeda Aivazoglou; Rafael Baches Jorge; Edmar Zanoteli; Artur R C Fernandes
Journal:  Curr Rheumatol Rep       Date:  2019-02-14       Impact factor: 4.592

Review 5.  Myositis Mimics.

Authors:  E Harlan Michelle; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

Review 6.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

7.  Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.

Authors:  Thomas E Lloyd; Lisa Christopher-Stine; Iago Pinal-Fernandez; Eleni Tiniakou; Michelle Petri; Alan Baer; Sonye K Danoff; Katherine Pak; Livia A Casciola-Rosen; Andrew L Mammen
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-01       Impact factor: 4.794

8.  A computational framework for converting textual clinical diagnostic criteria into the quality data model.

Authors:  Na Hong; Dingcheng Li; Yue Yu; Qiongying Xiu; Hongfang Liu; Guoqian Jiang
Journal:  J Biomed Inform       Date:  2016-07-19       Impact factor: 6.317

9.  PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome.

Authors:  David F Fiorentino; Matthew Presby; Alan N Baer; Michelle Petri; Kerri E Rieger; Mark Soloski; Antony Rosen; Andrew L Mammen; Lisa Christopher-Stine; Livia Casciola-Rosen
Journal:  Ann Rheum Dis       Date:  2015-08-07       Impact factor: 19.103

Review 10.  Updates on the Immunopathology in Idiopathic Inflammatory Myopathies.

Authors:  Akinori Uruha; Hans-Hilmar Goebel; Werner Stenzel
Journal:  Curr Rheumatol Rep       Date:  2021-07-01       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.